EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device

Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases.

EnClear Therapies has raised a $10 million Series A round of financing from a syndicate of investors to advance a device that it says could help treat neurodegenerative diseases by filtering out such proteins from cerebral spinal fluid (CSF), the clear liquid that surrounds the brain and spinal cord. CEO Anthony DesPasqua likens the process to a dialysis-like method that could help slow disease progression.